Comparable Outcome of Alternative Donor and Matched Sibling Donor Hematopoietic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia in First or Second Remission Using Alemtuzumab in a Myeloablative Conditioning Regimen

HLA-matched sibling donor (MSD) stem cell transplantation can cure >60% of pediatric patients with acute lymphoblastic leukemia (ALL), but

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2008-11, Vol.14 (11), p.1245-1252
Main Authors: Kennedy-Nasser, Alana A, Bollard, Catherine M, Myers, G. Doug, Leung, Kathryn S, Gottschalk, Stephen, Zhang, Yiqun, Liu, Hao, Heslop, Helen E, Brenner, Malcolm K, Krance, Robert A
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Adolescent
Adult
Alemtuzumab
Alternative donor stem cell transplantation
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm - administration & dosage
Antineoplastic Agents - administration & dosage
Child
Child, Preschool
Disease-Free Survival
Donor Selection - methods
Female
Graft Survival
Graft vs Host Disease - mortality
GVHD
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
Humans
Infant
Leukemia relapse
Living Donors
Male
National Health Programs
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Recurrence
Remission Induction
Retrospective Studies
Risk Factors
Siblings
Survival Rate
Transplantation Conditioning
Transplantation, Homologous
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HLA-matched sibling donor (MSD) stem cell transplantation can cure >60% of pediatric patients with acute lymphoblastic leukemia (ALL), but
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2008.08.010